Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
About CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a pioneering regenerative and aesthetic medicine company that is transforming the landscape of tissue repair, organ manufacturing, and medical aesthetics. Utilizing its proprietary recombinant human collagen (rhCollagen) technology, produced through a unique plant-based genetic engineering process, CollPlant addresses critical challenges in regenerative medicine with innovative, biocompatible solutions. The company’s products are designed to enable tissue regeneration, reduce immune response risks, and enhance patient outcomes across diverse medical fields.
Key Technologies and Products
At the heart of CollPlant’s innovation is its rhCollagen, a plant-derived, non-animal collagen that serves as the foundation for its product portfolio. This collagen is recognized for its superior biocompatibility, safety, and ability to support tissue regeneration. The company’s flagship offerings include:
- rhCollagen BioInk: A cutting-edge bioink tailored for 3D bioprinting of tissues and organs. This bioink is a cornerstone for advancing organ manufacturing and regenerative medicine.
- Regenerative Breast Implants: A revolutionary solution in development, designed to regenerate natural breast tissue without eliciting immune responses. These implants target the $3 billion global breast implant market, providing a safer and more natural alternative to silicone implants.
- Vergenix™ STR: A soft tissue repair matrix for treating tendinopathy, combining rhCollagen with platelet-rich plasma (PRP) to promote healing and tendon repair.
- Vergenix™ FG: A wound repair matrix that accelerates the healing of acute and chronic wounds by providing a supportive scaffold for cell growth.
- Photocurable Dermal Filler: A next-generation filler under development for the medical aesthetics market, offering tissue regeneration and superior skin lifting capacity.
Strategic Collaborations
CollPlant has established strategic partnerships with industry leaders to accelerate innovation and commercialization. Notable collaborations include:
- AbbVie: A global commercialization agreement for dermal and soft tissue fillers, leveraging CollPlant’s rhCollagen technology and AbbVie’s expertise in aesthetics.
- Stratasys: A joint development initiative to create bioprinting solutions for regenerative breast implants, utilizing Stratasys’ P3 technology and CollPlant’s bioinks.
Market Potential and Competitive Edge
CollPlant operates in high-growth markets, including regenerative medicine, medical aesthetics, and orthobiologics. Its unique value proposition lies in its plant-based rhCollagen, which offers significant advantages over traditional animal-derived collagen, including reduced risk of immune reactions and enhanced biocompatibility. By addressing unmet needs in tissue repair and organ manufacturing, CollPlant is well-positioned to capitalize on opportunities in multi-billion-dollar markets.
Challenges and Future Outlook
While CollPlant’s innovative technology provides a competitive edge, the company faces challenges such as scaling production, navigating complex regulatory pathways, and maintaining its financial runway. However, its strong pipeline, strategic partnerships, and focus on sustainability—evidenced by its Environmental, Social, and Governance (ESG) initiatives—underscore its commitment to long-term growth and innovation.
Conclusion
CollPlant Biotechnologies Ltd. is at the forefront of ushering in a new era of regenerative medicine. Its proprietary rhCollagen technology, coupled with strategic collaborations and a robust product pipeline, positions it as a transformative player in the fields of tissue repair, organ manufacturing, and medical aesthetics. By addressing critical unmet needs with innovative, biocompatible solutions, CollPlant is poised to make a lasting impact on global healthcare.
CollPlant Biotechnologies (CLGN) reported its 2024 financial results and corporate updates, highlighting progress in its regenerative breast implant program targeting a $3 billion market opportunity. The company received a $2 million development payment from AbbVie in February 2025.
Key financial results for 2024 include: revenues of $515,000 (down from $11.0 million in 2023), net loss of $16.6 million ($1.45 per share), and cash position of $11.9 million as of December 31, 2024. The company implemented a 20% workforce reduction to extend operations through Q2 2026.
Notable developments include: successful printing of 200cc commercial-sized breast implants, promising six-month study data showing vascularization and tissue ingrowth, expansion of Vergenix STR distribution in Europe and Asia, and new patent grants in Japan for rhCollagen curable BioInks and in the US for photocurable dermal filler technology.
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, March 26, 2025, before U.S. markets open.
The company will host a conference call at 10:00 a.m. EST to discuss financial results and corporate updates. Investors can participate using the following dial-in numbers:
- U.S. investors: 1-877-407-9716
- International investors: 1-201-493-6779
- Israel investors: 1-809-406-247
CollPlant Biotechnologies (NASDAQ: CLGN) has announced the expansion of distribution channels for its VergenixSTR product in Europe and Asia. The company has signed new distribution agreements with companies in the Netherlands, Turkey, and India, covering territories including Benelux, Spain, India, and Turkey.
The first shipment to the Benelux and Spain distributor, which specializes in orthopedic medical device sales, was made in February 2025. The Turkish and Indian distributors are finalizing regulatory processes with local authorities, aiming to begin sales in 2025.
VergenixSTR, based on CollPlant's rhCollagen technology, is designed to treat tendinopathy in various tendons including elbow, rotator cuffs, patellar, Achilles, and hand tendons. The product combines cross-linked rhCollagen with Platelet-rich plasma (PRP) to form a gel matrix that enables localized sustained release of growth factors at injury sites for optimal healing.
CollPlant Biotechnologies (NASDAQ: CLGN) announced several corporate updates. The company was granted U.S. Patent No. 12,186,449 for its photocurable dermal filler product candidate, extending protection until May 2039. The patent covers polymerizable solutions containing modified recombinant human collagen (rhCollagen) and other components like hyaluronic acid.
Under its partnership with AbbVie, CollPlant received a $2 million contingent payment. AbbVie is currently reviewing interim results from the first cohort of patients in dermal filler clinical trials initiated in 2023.
The company implemented cost-cutting measures, including a 20% workforce reduction, to extend its cash runway until at least Q2 2026. CollPlant will focus on advancing its product pipeline, particularly the development of its regenerative breast implant product candidate towards clinical phase.
CollPlant Biotechnologies (NASDAQ: CLGN) reported Q3 2024 financial results, highlighting promising developments in its regenerative breast implant program. The company achieved significant implant vascularization and rapid native tissue ingrowth in pre-clinical trials with 200cc commercial-sized implants. Q3 revenues were $4,000 compared to $43,000 in Q3 2023. Net loss was $4.3 million ($0.38 per share). Cash position stood at $15.4 million as of September 30, 2024, providing runway until end of 2025. The company is prioritizing non-dilutive funding through new collaborations while maintaining its ongoing partnership with AbbVie for dermal filler development.
CollPlant Biotechnologies (NASDAQ: CLGN) has announced it will release its third quarter 2024 financial results on Wednesday, November 27, 2024, before U.S. markets open. The company will host a conference call and webcast at 10:00 a.m. EST on the same day to discuss the results and provide corporate updates. Investors can participate via phone or through a live webcast available on the company's investor relations website. Questions for management can be submitted in advance via email.
CollPlant Biotechnologies (NASDAQ: CLGN) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Initiated pre-clinical trial with 200cc rhCollagen-based regenerative breast implants printed with Stratasys' Origin® 3D printer
- Breast implants could address a $3.0 billion market opportunity
- Q2 revenues were $249,000, down from $10.2 million in Q2 2023 due to a one-time milestone payment in the prior year
- Q2 GAAP net loss was $4.2 million or $0.37 per share
- Cash and cash equivalents of $18.9 million as of June 30, 2024
- Cash runway expected to last until at least the end of 2025
The company is advancing its regenerative breast implant program and released its first ESG report. CollPlant aims to lead in regenerative medicine with its innovative collagen technology.
CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys (Nasdaq: SSYS) have initiated a pre-clinical study for 3D-printed regenerative breast implants. The study focuses on 200cc commercial-sized implants produced using CollPlant's rhCollagen-based bioinks on a Stratasys Origin® printer. The innovative implants aim to promote natural breast tissue growth and completely degrade over time, potentially revolutionizing both reconstructive and aesthetic procedures in the $3 billion breast implant market.
The collaboration leverages Stratasys' 3D printing expertise and CollPlant's regenerative medicine technology. Initial results are expected in the first half of 2025. Previous pre-clinical studies have shown promising results, including neovascularization and tissue regeneration without adverse reactions.
CollPlant Biotechnologies (CLGN) and Stratasys (SSYS) have initiated a pre-clinical study for 3D-printed regenerative breast implants. The 200cc commercial-sized implants, made using CollPlant's rhCollagen-based bioinks and printed on a Stratasys Origin® printer, aim to promote natural breast tissue growth and completely degrade over time. This innovation targets the $3 billion breast implant market, offering a potential alternative to traditional silicone implants and autologous fat transfer procedures.
The collaboration focuses on developing a bioprinting solution and scaling up the fabrication process. Initial results from the study are expected in the first half of 2025. Previous pre-clinical studies have shown promising results, including neovascularization and tissue regeneration without adverse reactions.
CollPlant Biotechnologies (Nasdaq: CLGN), a leader in regenerative and aesthetics medicine, has announced its upcoming financial report and conference call for the second quarter of 2024. The company, known for its innovative non-animal-derived collagen technologies, will release its financial statements on Tuesday, August 20, 2024, before U.S. markets open.
A conference call and webcast are scheduled for 10:00 a.m. EDT on the same day. Investors can participate using various dial-in numbers based on their location. A live webcast will also be available in listen-only mode. To streamline the process, CollPlant offers a Call me™ feature for easy access. Investors can submit questions in advance by emailing Dan Ferry at LifeSci Advisors
FAQ
What is the current stock price of Collplant Biotechnologies (CLGN)?
What is the market cap of Collplant Biotechnologies (CLGN)?
What is CollPlant Biotechnologies Ltd. known for?
What is rhCollagen, and why is it significant?
What are CollPlant’s key products?
Who are CollPlant’s strategic partners?
What markets does CollPlant target?
What makes CollPlant’s products unique?
What is the significance of CollPlant’s regenerative breast implants?
How does CollPlant generate revenue?
What challenges does CollPlant face?
What are CollPlant’s sustainability initiatives?
